Madrigal Pharmaceuticals, Inc. (MDGL)
NasdaqGS · USD · Healthcare · Biotechnology
$437.74 (+0.81%) as of
Key statistics
- Market cap
- 10.11B
- Forward P/E
- 45.48
- EPS (TTM)
- -12.85
- Dividend yield
- 0.00%
- 52-week range
- 393.61 – 615.00
- Beta
- -1.05
- Revenue (TTM)
- 1.28B
- Profit margin
- -25.32%
- Analyst target
- $685.22
- Volume
- 275.78k
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- West Conshohocken, PA, United States
- Employees
- 915
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.